Artificial Intelligence
Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates
Strategic Highlights
- Received an issued US Patent titled “High Throughput Optical Assay of Human Mixed Cell Population Spheroids” by the United States Patent and Trademark Office (USPTO). The patent covers the use of spheroids and organoids for drug discovery.
- Entered into a strategic collaboration with Ordaōs Bio and Cellaria, Inc. to execute an integrated model for rapid iteration of therapeutic design using artificial intelligence (“AI”) and human-derived in vitro ‘avatar clinical trials’ to enable the design, development, and testing of potential therapeutics on targeted patient populations, during preclinical discovery with a primary focus in oncology.
- Completed a large primary screening of AI-generated novel compounds for Rett Syndrome yielding promising results, including a first round of hit expansion screening across two novel targets.
- Elevated our syngeneic bladder instillation model into toxicology screening, which will be performed in vivoPharm’s animal models.
- Progressed internal programs that apply Vyant Bio’s expertise with human-derived cell-based organoids to explore neurodegenerative disorders, including Parkinson’s and Alzheimer’s disease.
- Commenced the development of AI-based molecule and biologic creation for in-vitro testing through in-silico structure-function prediction.
- Cash position at June 30, 2021 was $26.5 million.
CHERRY HILL, N.J., Aug. 16, 2021 (GLOBE NEWSWIRE) — Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related diseases. Today, Vyant Bio reports its Second Quarter 2021 strategic and business updates in a conference call scheduled for 4:30 p.m. ET.
“We have achieved a tremendous amount of momentum in the first 90 days since launching the Vyant Bio brand and completing the merger we announced at the end of March 2021. Vyant Bio is committed to transforming the way drugs are discovered by quickly adapting to exciting new technologies and combining capabilities in ways that leverage their strengths,” stated Jay Roberts, CEO of Vyant Bio. “Our internal teams of scientists, data scientists and engineers, coupled with the capabilities of select strategic partners that are now integrated into our platform, allow us all to work together to design and develop superior therapeutics and position us to build a robust pipeline of novel therapeutics targeting degenerative and developmental neurological disorders and cancers with high unmet needs.”
Vyant Bio’s drug discovery platform uses both human-induced pluripotent stem cell-derived (hiPSC) and primary human cell organoids as proprietary disease models combined with analysis of human genetics and the use of machine learning algorithms for the identification of new targets, validation of known targets, and high-throughput screening for drug discovery. Vyant Bio’s drug discovery platform is intended to overcome the shortcomings of traditional drug discovery efforts that rely more heavily on insights from animal models to identify targets and to develop therapies intended for human disease. The Company is currently focused on the specific utility for the identification of targets and therapies in CNS and Oncology.
The Company filed its quarterly report for the Second Quarter 2021 on Form 10-Q today with the Securities and Exchange Commission. Please refer to our Form 10-Q for more detailed information with respect to our financial results for the three and six months ended June 30, 2021.
SECOND QUARTER 2021 FINANCIAL RESULTS1
As StemoniX, Inc. was deemed to have acquired Cancer Genetics, Inc. for accounting purposes and the Merger closed on March 30, 2021, the Company’s Second Quarter 2021 financial results include the post-merger results of the combined companies, now known as Vyant Bio. The analysis below excludes the Second Quarter 2020 results as they are based solely on StemoniX’s historical stand-alone operations and therefore do not reflect the post-merger enterprise.
Cash and cash equivalents totaled $26.5 million as of June 30, 2021.
Total revenues were $1.9 million for the three months ended June 30, 2021. Cost of goods sold – service aggregated to $1.0 million for the three months ended June 30, 2021 resulting in a cost of goods sold of 56% of service revenues. Cost of goods sold – product aggregated to $345 thousand for the three months ended June 30, 2021 resulting in a cost of goods sold gross margin deficit of $229 thousand. Our product manufacturing capabilities currently have excess capacity to support future growth. Research and development expenses were $910 thousand for the three months ended June 30, 2021. Selling, general and administrative expenses, which include public company costs and non-cash expenses of $620 thousand, were $3.7 million for the three months ended June 30, 2021.
While the Company executes its drug development strategy for long-term growth, the Company currently generates revenue from its vivoPharm and StemoniX subsidiaries. On a pro forma basis, assuming the Merger occurred on January 1, 2020, revenues for the three and six-month ended June 30, 2021 were $1.9 million and $3.8 million, respectively, as compared with $1.5 million and $3.1 million for the respective prior-year periods. On a pro forma basis, revenues increased by 26% and 21% in the current-year three and six-month periods as compared with the same prior-year periods.
1Pro forma information gives effect to the Merger between Cancer Genetics, Inc. and StemoniX, Inc. as if the Merger had occurred as of January 1, 2020. The pro forma information is presented solely for informational purposes and is not necessarily indicative of the combined results of operations or financial position that might have been achieved for the periods or dates indicated, nor is it necessarily indicative of the future results of the Company.
Vyant Bio’s Conference Call and Webcast and Information
Vyant Bio’s management will host a conference call on Monday, August 16, 2021 at 4:30pm ET to discuss the Second Quarter 2021 results and provide strategic business updates, as well as answer questions. Event information is below:
Event: Investor Conference Call and Webcast for Second Quarter 2021
Date: Monday, August 16, 2021
Time: 4:30pm ET
Dial In: Toll Free: +1.844.369.8774
Webcast: https://www.webcaster4.com/Webcast/Page/2756/42335
The event will be recorded and archived. Replay information is below:
Conference Call Replay Information:
Toll Free: +1.877.481.4010 PIN: 42335
Webcast Replay Information: https://ir.vyantbio.com/news-events/ir-calendar
ABOUT VYANT BIO, INC.
Vyant Bio, Inc. is emerging as an advanced biotechnology drug discovery company. Vyant Bio is rapidly identifying small and large molecule therapeutics to treat central nervous system (CNS) and oncology-related disorders. With leading-edge capabilities in data science, biological and chemical sciences, engineering, and regulatory affairs, Vyant Bio capitalizes on in silico, human cell-derived in vitro disease models, and in vivo discovery technologies to identify novel biological targets and valuable therapeutics for patients. Vyant Bio operates two wholly-owned subsidiaries, StemoniX and vivoPharm. Formerly known as Cancer Genetics, Inc., the Company’s name was changed to Vyant Bio, Inc. in March 2021. Vyant Bio is headquartered in the US, with offices in Europe, and Australia.
StemoniX is empowering the discovery of new medicines through the convergence of novel human biology and software technologies. StemoniX develops and manufactures high-density, at-scale human induced pluripotent stem cell-derived neural and cardiac screening platforms for drug discovery and development. Predictive, accurate, and consistent, these human models enable scientists to conduct research quickly and economically with improved outcomes in a simplified workflow. Through collaborations with drug discovery organizations, StemoniX tests compounds in-house, creates new cell-based disease models, and operationalizes custom human iPSC-derived disease models at large scale for high-throughput screening. With leading-edge human iPSC technologies and data science, StemoniX is helping global institutions bring the most promising medicines to patients.
vivoPharm offers proprietary preclinical test systems supporting clinical diagnostic offerings at early stages valued by the pharmaceutical industry, biotechnology companies, and academic research centers. vivoPharm is focused on precision and translational medicine to drive drug discovery and novel therapies. vivoPharm specializes in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of in vitro and in vivo data and reports, as needed for Investigational New Drug filings. vivoPharm operates in The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) accredited and GLP compliant audited facilities.
For more information, please visit or follow Vyant Bio at:
Internet: www.vyantbio.com
LinkedIn: https://www.linkedin.com/company/vyant-bio
Twitter: @VyantBio
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.’s expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future strategic transactions in this press release constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, discover drug candidates, partner with pharmaceutical and other biotechnology companies, achieve profitability and increase sales of our services, maintain our existing customer base and avoid cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs, realize the anticipated benefits of the merger of StemoniX, Inc. and Cancer Genetics, Inc., and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2020, and any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio disclaims any obligation to update these forward-looking statements.
Investor Contact:
Jennifer K. Zimmons. Ph.D., MBA
Investor Relations
Zimmons International Communications, Inc.
Email: [email protected]
Phone: +1.917.214.3514
Source: Vyant Bio, Inc.
###
Vyant Bio, Inc.
(Formerly Known as Cancer Genetics, Inc.)
Consolidated Balance Sheets
(unaudited)
(Shares and USD in Thousands)
| June 30, | December 31, | |||||||
| 2021 | 2020 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 26,485 | $ | 792 | ||||
| Trade accounts and other receivables | 1,261 | 357 | ||||||
| Inventory | 407 | 415 | ||||||
| Patent held for sale | 30 | – | ||||||
| Prepaid expenses and other current assets | 1,890 | 223 | ||||||
| Total current assets | 30,073 | 1,787 | ||||||
| Non-current assets: | ||||||||
| Fixed assets, net | 1,654 | 1,031 | ||||||
| Operating lease right-to-use assets, net | 1,068 | 1,095 | ||||||
| Intangible assets, net | 9,262 | – | ||||||
| Goodwill | 21,703 | – | ||||||
| Long-term prepaid expenses and other assets | 1,641 | 136 | ||||||
| Total non-current assets | 35,328 | 2,262 | ||||||
| Total Assets | $ | 65,401 | $ | 4,049 | ||||
| Liabilities, Temporary Equity and Stockholders’ Equity (Deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,016 | $ | 1,300 | ||||
| Accrued expenses | 1,246 | 162 | ||||||
| Deferred revenue | 1,416 | 92 | ||||||
| Obligations under operating leases, current portion | 490 | 486 | ||||||
| Obligation under finance lease, current portion | 31 | – | ||||||
| Other current liabilities | 3 | 9 | ||||||
| Current liabilities of discontinued operations | 436 | – | ||||||
| Total current liabilities | 4,638 | 2,049 | ||||||
| Obligations under operating leases, less current portion | 576 | 627 | ||||||
| Obligations under finance leases, less current portion | 66 | – | ||||||
| Share-settlement obligation derivative | – | 1,690 | ||||||
| Warrant liability | 1 | – | ||||||
| Accrued interest | – | 277 | ||||||
| Long-term debt | 57 | 6,839 | ||||||
| Total Liabilities | 5,338 | 11,482 | ||||||
| Commitments and Contingencies | – | – | ||||||
| Temporary Equity | ||||||||
| Series A Convertible Preferred stock, $0.0001 par value; 4,700 shares authorized, 0 and 4,612 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively (liquidation value of $0 and $11,732, respectively, as of June 30, 2021 and December 31, 2020) | – | 12,356 | ||||||
| Series B Convertible Preferred stock, $0.0001 par value; 4,700 shares authorized, 0 and 3,489 shares issued and outstanding, as of June 30, 2021 and December 31, 2020, respectively (liquidation value of $0 and $15,707, respectively, as of June 30, 2021 and December 31, 2020) | – | 16,651 | ||||||
| Series C Convertible Preferred stock, $0.0001 par value; 2,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2021 and December 31, 2020 (liquidation value of $0 as of June 30, 2021 and December 31, 2020) | – | – | ||||||
| Total Temporary Equity | – | 29,007 | ||||||
| Stockholders’ Equity (Deficit) | ||||||||
| Preferred stock, authorized 9,764 shares $0.0001 par value, none issued | – | – | ||||||
| Common stock, authorized 100,000 shares, $0.0001 par value, 28,985 and 2,594 shares issued and outstanding as of June 30, 2021, and December 31, 2020, respectively | 3 | – | ||||||
| Additional paid-in capital | 109,567 | 1,514 | ||||||
| Accumulated comprehensive loss | (1 | ) | – | |||||
| Accumulated deficit | (49,506 | ) | (37,954 | ) | ||||
| Total Stockholders’ Equity (Deficit) | 60,063 | (36,440 | ) | |||||
| Total Liabilities and Stockholders’ Equity (Deficit) | $ | 65,401 | $ | 4,049 | ||||
Vyant Bio, Inc.
(Formerly Known as Cancer Genetics, Inc.)
Consolidated Statements of Operations
(Shares and USD in Thousands)
| Three months ended June 30 | Six months ended June 30 | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenues: | ||||||||||||||||
| Service | $ | 1,831 | $ | 41 | $ | 1,947 | $ | 176 | ||||||||
| Product | 116 | 58 | 222 | 91 | ||||||||||||
| Total revenues | 1,947 | 99 | 2,169 | 267 | ||||||||||||
| Operating costs and expenses: | ||||||||||||||||
| Cost of goods sold – service | 1,027 | 38 | 1,116 | 170 | ||||||||||||
| Cost of goods sold – product | 345 | 147 | 741 | 313 | ||||||||||||
| Research and development | 910 | 593 | 1,730 | 1,602 | ||||||||||||
| Selling, general and administrative | 3,664 | 408 | 4,880 | 1,241 | ||||||||||||
| Merger related costs | 165 | – | 2,310 | – | ||||||||||||
| Total operating costs and expenses | 6,111 | 1,186 | 10,777 | 3,326 | ||||||||||||
| Loss from operations | (4,164 | ) | (1,087 | ) | (8,608 | ) | (3,059 | ) | ||||||||
| Other (expense) income: | ||||||||||||||||
| Change in fair value of warrant liability | – | – | 214 | – | ||||||||||||
| Change in fair value of share-settlement obligation derivative | – | (211 | ) | (250 | ) | (211 | ) | |||||||||
| Loss on debt conversions | – | – | (2,518 | ) | – | |||||||||||
| Other income (expense) | (25 | ) | 1 | (25 | ) | 1 | ||||||||||
| Interest income | 3 | – | 3 | – | ||||||||||||
| Interest expense | – | (36 | ) | (368 | ) | (37 | ) | |||||||||
| Total other (expense) income | (22 | ) | (246 | ) | (2,944 | ) | (247 | ) | ||||||||
| Loss before income taxes | (4,186 | ) | (1,333 | ) | (11,552 | ) | (3,306 | ) | ||||||||
| Income tax expense (benefit) | – | – | – | – | ||||||||||||
| Net loss | $ | (4,186 | ) | $ | (1,333 | ) | $ | (11,552 | ) | $ | (3,306 | ) | ||||
| Net loss per common share: | ||||||||||||||||
| Net loss per share attributable to common stock – Basic and Diluted | $ | (0.14 | ) | $ | (0.54 | ) | $ | (0.72 | ) | $ | (1.34 | ) | ||||
| Weighted average shares outstanding: | ||||||||||||||||
| Weighted average common shares outstanding – Basic and Diluted | 28,985 | 2,468 | 16,156 | 2,464 | ||||||||||||
Vyant Bio, Inc.
(Formerly Known as Cancer Genetics, Inc.)
Consolidated Statements of Cash Flows
(unaudited)
(USD in Thousands)
| Six months ended June 30, | ||||||||
| 2021 | 2020 | |||||||
| Cash Flows from Operating Activities: | ||||||||
| Net loss | $ | (11,552 | ) | $ | (3,306 | ) | ||
| Reconciliation of net loss to net cash used in operating activities: | ||||||||
| Stock-based compensation | 728 | 133 | ||||||
| Amortization of operating lease right-of-use assets | 135 | 244 | ||||||
| Depreciation and amortization expense | 567 | 287 | ||||||
| Change in fair value of share-settlement obligation derivative | 250 | 211 | ||||||
| Change in fair value of warrant liability | (214 | ) | – | |||||
| Change in fair value of 2020 Convertible Note with fair value election | 4 | – | ||||||
| Accretion of debt discount | 173 | 13 | ||||||
| Loss on conversion of debt | 2,518 | – | ||||||
| PPP loan forgiveness | – | (649 | ) | |||||
| Loss on equipment | 6 | 29 | ||||||
| Changes in operating assets and liabilities, net of impacts of business combination: | ||||||||
| Trade accounts and other receivables | (34 | ) | (54 | ) | ||||
| Inventory | 8 | (50 | ) | |||||
| Prepaid expenses and other current assets | (1,208 | ) | 151 | |||||
| Accounts payable | (1,081 | ) | 459 | |||||
| PPP loan proceeds | – | 730 | ||||||
| Obligations under operating leases | (162 | ) | (247 | ) | ||||
| Accrued expenses and other current liabilities | (808 | ) | 12 | |||||
| Net cash used in operating activities | (10,670) | (2,037 | ) | |||||
| Cash Flows from Investing Activities: | ||||||||
| Purchase of equipment | (520 | ) | – | |||||
| Proceeds from sale of equipment | – | 17 | ||||||
| Cash acquired from acquisition | 30,163 | – | ||||||
| Net cash provided by investing activities | 29,643 | 17 | ||||||
| Cash Flows from Financing Activities: | ||||||||
| EIDL loan proceeds | – | 67 | ||||||
| Issuance of common stock | 4 | 23 | ||||||
| Issuance of Series B Preferred stock, net of issuance costs | – | 1,250 | ||||||
| Issuance of Series C Preferred stock, net of issuance costs | 1,786 | – | ||||||
| 2020 Convertible Note proceeds | 5,022 | 332 | ||||||
| Principal payments on long-term debt | (82 | ) | – | |||||
| Proceeds from related party notes | – | 80 | ||||||
| Principal payments on obligations under finance leases | (10 | ) | (37 | ) | ||||
| Net cash provided by financing activities | 6,720 | 1,715 | ||||||
| Net increase (decrease) in cash and cash equivalents | 25,693 | (305 | ) | |||||
| Cash and cash equivalents, beginning of the period | 792 | 315 | ||||||
| Total cash and cash equivalents, end of period | $ | 26,485 | $ | 10 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid for interest | $ | – | $ | 7 | ||||
| Cash paid for income taxes | – | – | ||||||
| Non-cash investing activities: | ||||||||
| Fair value of non-cash merger consideration | $ | 59,920 | $ | – | ||||
| Equipment purchases in accounts payable | 37 | – | ||||||
| Right-of-use assets obtained in exchange for new operating lease liabilities | 83 | – | ||||||
| Non-cash financing activities: | ||||||||
| Conversion of Preferred Stock to Common Stock upon Merger | $ | 30,793 | $ | – | ||||
| Conversion of 2020 Convertible Notes and accrued interest to Common Stock upon Merger | 16,190 | – | ||||||
| Exchange of Series B Preferred stock for 2020 Convertible Notes | – | 2,569 | ||||||
| Reclass warrant liability to equity upon Merger | 421 | – | ||||||
Pro forma information gives effect to the Merger between Cancer Genetics, Inc. and StemoniX, Inc. as if the Merger had occurred as of January 1, 2020. The pro forma information is presented solely for informational purposes and is not necessarily indicative of the combined results of operations or financial position that might have been achieved for the periods or dates indicated, nor is it necessarily indicative of the future results of the Company.
| For the three months ended June, 30 |
For the six months ended June 30, |
|||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Total revenues | $ | 1,947 | $ | 1,545 | $ | 3,788 | $ | 3,139 | ||||||||
| Net loss | (4,021 | ) | ( 2,689 | ) | (5,560 | ) | (5,799 | ) | ||||||||
| Pro forma loss per common share, basic and diluted | (0.14 | ) | (0.09 | ) | (0.19 | ) | (0.20 | ) | ||||||||
| Pro forma weighted average number of common shares basic and diluted | 28,985,924 | 28,830,441 | 28,973,370 | 28,826,652 | ||||||||||||
Artificial Intelligence
Group-IB takes part in a global operation to cripple Canadian Phishing-as-a-Service provider LabHost
SINGAPORE, April 18, 2024 /PRNewswire/ — Group-IB, a leading cybersecurity company aimed at investigating, preventing, and fight digital crime announced today that it participated in a coordinated global takedown operation against prominent Canadian Phishing-as-a-Service (PhaaS) provider LabHost, which has led to the arrest of 37 suspects across the United Kingdom and around the world by law enforcement agencies. As part of the operation, Group-IB also conducted an extensive analysis of LabHost’s criminal history and infrastructure, including insights into LabHost’s administrative platform and the services it provides to its purported user base which exceeds 2,000 subscribers worldwide, who illegally obtained around 480,000 card numbers, 64,000 pin numbers, and over 1 million passwords from victims used for websites and other online services, according to law enforcement agencies.
“By leveraging our Threat Intelligence and Digital Risk Protection, we are able to identify and monitor phishing attacks and websites like those deployed by LabHost and its subscribers around the world, enabling us to actively alert and protect our customers, and in turn, their customers as well,” said Dmitry Volkov, Chief Executive Officer of Group-IB. “Today’s takedown operation demonstrates the agility and responsiveness of our decentralized Digital Crime Resistance Centers, and how quickly we can provide immediate and local assistance wherever our customers may be.”
First uncovered in late 2021, LabHost emerged as a fully automated Phishing-as-a-Service (PhaaS) platform, streamlining the creation of phishing websites meticulously mirroring the interface and functionality of prominent banking, postal, and financial entities, aimed at intercepting, seizing, and profiting from users’ personal, credit card, and online banking credentials. Users are prompted to select from various “membership plans,” tailored to target businesses and individuals in either the United States and Canada, or globally, akin to mobile subscription models. These plans encompass “standard,” “premium,” and “world membership” tiers, priced between US$179 and US$300 monthly, with options for monthly, quarterly, or annual billing cycles.
For media inquiries, please contact [email protected]
Photo – https://mma.prnewswire.com/media/2391017/Group_IB.jpgPhoto – https://mma.prnewswire.com/media/2391018/Group_IB_2.jpgLogo – https://mma.prnewswire.com/media/1853638/4657466/Group_IB_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/group-ib-takes-part-in-a-global-operation-to-cripple-canadian-phishing-as-a-service-provider-labhost-302121388.html
Artificial Intelligence
Malaysia Data Center Market to Witness $3.97 Billion Investment Opportunities by 2029, Get Insights on 34 Existing Data Centers and 33 Upcoming Facilities across Malaysia – Arizton
CHICAGO, April 18, 2024 /PRNewswire/ — According to Arizton’s latest research report, the Malaysia data center market is growing at a CAGR of 13.92% during the forecast period.
To Know More, Download the Free Sample Report: https://www.arizton.com/market-reports/malaysia-data-center-market-size-analysis
Malaysia Data Center Market Report Scope
Report Attributes
Details
Market Size (Investment)
USD 3.97 Billion (2029)
Market Size (Area)
883 Thousand Sq. Feet (2029)
Market Size (Power Capacity)
163 MW (2029)
CAGR Investment (2023-2029)
13.92 %
Colocation Market Size (Revenue)
USD 1.23 Billion (2029)
Historic Year
2020-2022
Base Year
2023
Forecast Year
2024-2029
Over the next few years, Malaysia is poised to witness significant growth in data center investments, driven by the influx of operators like AirTrunk, Equinix, Princeton Digital Group, and other leading companies. Key hubs like Cyberjaya, Kuala Lumpur, and Johor Bahru are expected to see heightened activity, hosting most of the country’s data centers.
The wholesale colocation sector is projected to experience a revenue surge fueled by major cloud players like Microsoft, Google, and AWS. These companies have unveiled plans to establish dedicated cloud regions within Malaysia, with expected timelines for deployment within the next one to two years. This trend underscores Malaysia’s growing importance as a regional hub for data infrastructure and cloud services.
Malaysia is among the top expensive markets globally for developing data centers. Malaysia’s data center construction cost in 2023 stood at about $8.5-$10 million per MW, making it the costliest market in the APAC region after Singapore and Jakarta.
Investment Opportunities in the Malaysia Data Center Market
In November 2023, ST Telemedia Global Data Centres announced its plans to develop a new data center campus in Johor. The construction of the first building is likely to begin soon and become operational by 2025. The company formed a joint venture with Basis Bay to develop a new data center campus with two buildings, Cyberjaya DC.2 and STT Kuala Lumpur 1 in Cyberjaya, Selangor.In October 2023, EDGNEX Data Centres by DAMAC announced its plans to enter the APAC market for the first time; the company is considering a facility in Cyberjaya, Selangor. The expected investment can cross the $52 million mark.In October 2023, Infinaxis Data Centre Holdings, the joint venture between Gaw Capital Partners and A3 Capital, announced the construction of its first data center facility in Cyberjaya. The facility will have 10 data halls and will likely be operational by Q2 2025.In September 2023, EdgeConneX announced its plans to expand its footprint in Malaysia with the development of three data centers sites across Bukit Jalil, Kuala Lumpur, and Cyberjaya. The company plans to develop data centers in partnership with Cyberview.To Know More, Download the Free Sample Report: https://www.arizton.com/market-reports/malaysia-data-center-market-size-analysis
Market Trends
According to IRENA, in 2022, hydroenergy accounted for around 69% of the renewable energy capacity in Malaysia, followed by solar energy, which contributed about 21%, along with a 10% contribution by bioenergy.Malaysia aims to achieve the target of net-zero carbon emissions by 2050. To make this goal a reality, WWF-Malaysia is partnering with Boston Consulting Group to develop an independent joint study on the country’s optimal net zero pathway.The government of Malaysia has established a green tariff scheme to support its carbon-neutrality target. Under the scheme, subscribers can get electricity from solar or hydro sources instead of fossil fuel sources.Mergers, acquisitions, joint ventures, and partnerships are key strategies employed by operators to expand their portfolios and global footprint. For example:
In December 2023, Chindata Group merged with BCPE Chivalry Merger Sub, a wholly owned subsidiary of BCPE Chivalry Bidco, completing its transition to a private company from a public one.November 2023 saw ST Telemedia Global Data Centres, in a joint venture with Basis Bay, announcing plans to develop a new data center campus with two buildings in Cyberjaya, Selangor.A3 Capital and Gaw Capital Partners formed a joint venture in February 2023 to establish Infinaxis Data Centre Holdings to develop and operate data centers across Malaysia and Southeast Asia.MN Holdings, an engineering services and solutions company, signed a Memorandum of Understanding (MoU) in April 2023 with Shanghai DC-Science, outlining an investment of approximately $600 million to develop a data center site at the Sedenak Tech Park, Johor.Why Should You Buy This Research?
Market size is available regarding investment, area, power capacity, and Malaysia colocation market revenue.An assessment of the data center investment in Malaysia by colocation, hyperscale, and enterprise operators.Investments in the area (square feet) and power capacity (MW) across cities in the country.A detailed study of the existing Malaysia data center market landscape, an in-depth market analysis, and insightful predictions about market size during the forecast period.Snapshot of existing and upcoming third-party data center facilities in MalaysiaFacilities Covered (Existing): 34Facilities Identified (Upcoming): 33Coverage: 9 LocationsExisting vs. Upcoming (Area)Existing vs. Upcoming (IT Load Capacity)Data Center Colocation Market in MalaysiaColocation Market Revenue & Forecast (2023-2029)Wholesale vs. Retail Colocation Revenue (2023-2029)Retail Colocation PricingWholesale Colocation PricingThe Malaysia data center market investments are classified into IT, power, cooling, and general construction services with sizing and forecast.A comprehensive analysis of the latest trends, growth rate, potential opportunities, growth restraints, and prospects for the industry.Business overview and product offerings of prominent IT infrastructure providers, construction contractors, support infrastructure providers, and investors operating in the industry.A transparent research methodology and the analysis of the demand and supply aspects of the industry.Buy this Research @ https://www.arizton.com/market-reports/malaysia-data-center-market-size-analysis
Post-Purchase Benefit
1hr of free analyst discussion10% off on customizationThe Report Includes the Investment in the Following Areas:
IT InfrastructureServersStorage SystemsNetwork InfrastructureElectrical InfrastructureUPS SystemsGeneratorsSwitches & SwitchgearsPDUsOther Electrical InfrastructureMechanical InfrastructureCooling SystemsRack CabinetsOther Mechanical InfrastructureCooling SystemsCRAC and CRAHChillersCooling Tower and Dry CoolersOther Cooling UnitsGeneral ConstructionCore & Shell DevelopmentInstallation & Commissioning ServicesBuilding & Engineering DesignFire Detection & Suppression SystemsPhysical SecurityData Center Infrastructure Management (DCIM)Tier StandardTier I & Tier IITier IIITier IV GeographySelangorJohorOther StatesVendor Landscape
IT Infrastructure Providers
Cisco SystemsDell TechnologiesFujitsuHewlett Packard EnterpriseHuawei TechnologiesIBMInspurLenovoNetAppData Center Construction Contractors & Sub-Contractors
Advance Power EngineeringAsima ArchitectsAVO TechnologyB-Global TechCTC-GlobalCSF GroupCyclect GroupDSCO GroupGamudaGCM TechnologiesHSS EngineersISGKienta Engineering ConstructionLSK EngineeringMES GroupM+W Group (Exyte)MN HoldingsNakanoNTT FACILITIESPowerware SystemsS5 EngineeringShaw ArchitectSunway Construction GroupUnique CentralSupport Infrastructure Providers
ABBCaterpillarCumminsEatonFuji ElectricHITEC Power ProtectionKOHLER PowerLegrandMitsubishi ElectricNarada Power SourcePiller Power SystemsRittalRolls-RoyceSchneider ElectricSiemensSocomecSTULZTraneVertivData Center Investors
Bridge Data CentresEdge CentresGDS ServicesIRIX (PP TELECOMMUNICATION)Keppel Data CentresNTT DATAOpen DCTM OneVantage Data CentersYTL Data Center HoldingsNew Entrants
AirTrunkAmazon Web Services (AWS)EdgeConneXEquinixFutureData (Cyclect Group + TSG Group)Googlei-BerhadInfinaxis Data Centre HoldingsMN Holdings + Shanghai DC-ScienceMicrosoftNEXTDCPrinceton Digital GroupRegal OrionSingtelST Telemedia Global Data CentresYondrTo Know More, Download the Free Sample Report: https://www.arizton.com/market-reports/malaysia-data-center-market-size-analysis
Key Questions Answered in the Report:
What factors are driving the Malaysian data center industry?
How big is the Malaysia data center market?
How many MW of power capacity will be added across Malaysia during 2024 to 2029?
What is the growth rate of the Malaysia data center market?
Which states are included in the Malaysia data center market report?
Get the Detailed TOC @ https://www.arizton.com/market-reports/malaysia-data-center-market-size-analysis
Check Out Some of the Top-Selling Research Reports:
Indonesia Data Center Market – Investment Analysis & Growth Opportunities 2024-2029
Thailand Data Center Colocation Market – Supply and Demand Analysis 2024-2029
Singapore Data Center Market – Investment Analysis & Growth Opportunities 2023-2028
Australia Data Center Market – Investment Analysis & Growth Opportunities 2023–2028
Why Arizton?
100% Customer Satisfaction
24×7 availability – we are always there when you need us
200+ Fortune 500 Companies trust Arizton’s report
80% of our reports are exclusive and first in the industry
100% more data and analysis
1500+ reports published till date
About Us:
Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.
We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.
Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
Contact UsCall: +1-312-235-2040 +1 302 469 0707 Mail: [email protected] Contact Us: https://www.arizton.com/contact-us Blog: https://www.arizton.com/blog Website: https://www.arizton.com/
Photo: https://mma.prnewswire.com/media/2390971/Malaysia_Data_Center_Market.jpgLogo: https://mma.prnewswire.com/media/818553/Arizton_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/malaysia-data-center-market-to-witness-3-97-billion-investment-opportunities-by-2029–get-insights-on-34-existing-data-centers-and-33-upcoming-facilities-across-malaysia—arizton-302120944.html
Artificial Intelligence
VIVOTEK Launches Successful Make Tomorrow Easier, Today! Vision During ISC West 2024
TAIPEI, April 18, 2024 /PRNewswire/ — VIVOTEK (3454-TW), the global leading IP security solution provider, announces that last week’s 2024 ISC West trade show in Las Vegas was a tremendous success as it unveiled the 2024 theme Make Tomorrow Easier, Today! to partners, attendees, and the media. Make Analytics Easier, Make Cloud Easier, Make Search Easier, and Make Integration Easier were the core essential components of the 2024 theme, and both the booth staff and visitors were very busy discussing its vision throughout the show. This also demonstrates that VIVOTEK’s AI security solutions and cloud-based service VORTEX attracted interests by many customers for their rich versatility in applications.
From the outset, it was clear that this year’s ISC West was going to surpass previous editions. There were more engagements, and these engagements lasted longer than the past as attendees and the media were hyper-focused on VORTEX, its new camera solutions, AI integration, re-launch of VIVOTEK Premium Partner Program, additional technology solutions, and the roll-out of the 2024 theme.
AI has quickly become a priority in the security industry, and it was a focal point of VIVOTEK’s strategy during the show as well. During its many sales and marketing meetings at ISC West, discussions primarily revolved around how to integrate AI into the product lines and software platforms, much to the gratification of its partners who are seeing a quickly growing need for this technology to satisfy their customers’ needs.
As many of its customers may know by now, VIVOTEK recently entered into an integration partnership with Kisi, a modern cloud-based access control solution based in Brooklyn, New York. This partnership aims to secure physical spaces dedicated to providing a seamless and efficient user experience, making Kisi ideally suited as a VIVOTEK partner. During ISC West, VIVOTEK provided Kisi with a station in the booth to perform demonstrations, which proved to be very popular during the show.
Throughout the event, VORTEX remained a central focal point and rapidly gained popularity among partners since its launch. This was evident throughout the show as the VORTEX station was continuously used for strategic demonstrations. As for the theme, attendees commended on how much they liked this year’s booth layout, how the message of “Making Tomorrow Easier, Today” was delivered in every stations, how accessible the staff was in meeting with them, and how much they enjoyed the partner reception party.
VIVOTEK’s commitment to innovation and customer-centric solutions shone brightly at ISC West, as evident in the overwhelmingly positive feedbacks it received from partners, end users, media, and even other exhibit manufacturers. VIVOTEK extends heartfelt thanks to everyone who contributed to making this year’s ISC West a tremendous success. We look forward to making next year’s ISC West even better!
Photo – https://mma.prnewswire.com/media/2390930/1.jpg
View original content:https://www.prnewswire.co.uk/news-releases/vivotek-launches-successful-make-tomorrow-easier-today-vision-during-isc-west-2024-302121042.html
-
Artificial Intelligence6 days agoIn-Depth Analysis of Germany and France Data Center Markets: Germany Poised to Contribute Over $12.24 Billion Opportunities in the Next 6 Years – Arizton
-
Uncategorized6 days agoArm CEO Rene Haas will be delivering a Partner’s Event Speech at COMPUTEX 2024
-
Uncategorized6 days ago
BJEI: A New Record of High Performance in 2023 and a New Pattern of Diversified and Coordinated Development
-
Uncategorized6 days ago
Integrity Food Marketing Joins Forces with CA Ferolie to Expand East Coast Reach from Maine to Florida
-
Uncategorized6 days ago
Dimethyl Carbonate Market worth $1.9 billion by 2028 – Exclusive Report by MarketsandMarkets™
-
Artificial Intelligence6 days agoCogX Festival Set to Debut in Los Angeles at Century Plaza on May 7th, 2024
-
Artificial Intelligence6 days ago
aelf Leads the Fusion of AI and Blockchain to Shape the Future of Technology
-
Artificial Intelligence6 days agoXinhua Silk Road: Zoomlion Access pursues high-quality development with aerial work machinery sector innovation
